cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Genmab A S
7 own
4 watching
Current Price
$0
$0.01
(0.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,061.79M
52-Week High
52-Week High
47.5
52-Week Low
52-Week Low
26.19
Average Volume
Average Volume
0.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
13.3069
iconMarket Capitalization4,061.79M
icon52-Week High47.5
icon52-Week Low26.19
iconAverage Volume0.02M
iconDividend Yield--
iconP/E Ratio13.3069
What does the Genmab A S do?
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; a research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Read More
News & Events about Genmab A S.
Globe Newswire
20days ago
Company Announcement COPENHAGEN, Denmark; January 19, 2023 Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported thatmember of ...
Globe Newswire
1month ago
Company Announcement COPENHAGEN, Denmark; January 3, 2023 Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial...
Globe Newswire
1month ago
Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41stAnnual J.P. Morgan Healthcare Conference in San Francisco at 9:00 AM PST / 12:00 PM EST / 6:00 PM CET on January 11, 2023.The ...
Globe Newswire
1month ago
Media Release COPENHAGEN, Denmark; December 21, 2022 JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell non-Hodgkins lymphoma (NHL), including relapsed/refractory large B-cell lymphoma (LBCL) Genmab A/S (Nasdaq: ...
Business Wire
1month ago
Genmab A/S (Nasdaq: GMAB): JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell non-Hodgkins lymphoma (NHL), including relapsed/refractory large B-cell lymphoma (LBCL) Genmab A/S (Nasdaq: GMAB) today announced that...
Frequently Asked Questions
Frequently Asked Questions
What is Genmab A S share price today?
plus_minus_icon
Can Indians buy Genmab A S shares?
plus_minus_icon
How can I buy Genmab A S shares from India?
plus_minus_icon
Can Fractional shares of Genmab A S be purchased?
plus_minus_icon
What are the documents required to start investing in Genmab A S stocks?
plus_minus_icon
What is today’s traded volume of Genmab A S?
plus_minus_icon
What is today’s market capitalisation of Genmab A S?
plus_minus_icon
What is the 52-Week High and Low Range of Genmab A S?
plus_minus_icon
What percentage is Genmab A S down from its 52-Week High?
plus_minus_icon
What percentage is Genmab A S up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.01
(0.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
TRANSMEDICS GROUP INC
TRANSMEDICS GROUP INC
$67.27
$-0.58 (-0.85 %)
AdaptHealth Corp
AdaptHealth Corp
$20.59
$-0.06 (-0.29 %)
Abcam plc
Abcam plc
$15.86
$0.20 (1.28 %)
Inari Medical Inc
Inari Medical Inc
$55.71
$-0.83 (-1.47 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
TRANSMEDICS GROUP INC
TRANSMEDICS GROUP INC
$67.27
$-0.58 (-0.85 %)
AdaptHealth Corp
AdaptHealth Corp
$20.59
$-0.06 (-0.29 %)
Abcam plc
Abcam plc
$15.86
$0.20 (1.28 %)
Inari Medical Inc
Inari Medical Inc
$55.71
$-0.83 (-1.47 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00